Ravis W R, Hoke J F, Parsons D L
Department of Pharmacal Sciences, Auburn University, Alabama 36849.
Drug Metab Rev. 1991;23(3-4):375-411. doi: 10.3109/03602539109029765.
As a result of their ability to transport oxygen, PFC emulsions are being investigated for possible use in a wide variety of conditions. The recent FDA approval of F-DA to diminish myocardial ischemia during angioplasty is the first marketing approval for such a product in the world. The many potential uses of such products may result in their common application in the future, especially as new and better products are developed. The elimination, distribution, and tissue retention of PFC emulsions as well as the physiological changes that occur upon their administration have been the subject of many investigations. The results indicate that these agents may influence the pharmacokinetic properties of other drugs by a wide variety of mechanisms. Several studies have shown significant, but not necessarily consistent, changes in drug elimination and distribution following PFC emulsion infusion. Changes appear dependent on the drug examined, emulsion utilized, degree of blood exchange, species utilized, and the controls chosen for comparison. Often, the changes are time dependent indicating the importance of conducting long-term studies. While PFC emulsions do not appear to alter renal elimination of drugs, several studies have demonstrated that these agents have the potential to induce drug metabolism from several days to possibly months after exposure. Observed changes in drug volumes of distribution, which are often time dependent, may be due to changes in normal drug transport throughout the circulation and/or changes in membrane permeability and cell transport mechanisms. Changes in drug transport may result from depletion of plasma proteins or increases in alpha 1-acid glycoprotein levels due to trauma or PFC emulsion effects. The binding of drugs by PFC emulsion droplets varies greatly and PFC emulsion components displace some plasma protein bound drugs. The wide variability in the results and conclusions of the pharmacokinetic studies conducted to date emphasize the importance of utilizing adequate controls to identify which alterations are PFC emulsion specific.
由于全氟化合物(PFC)乳剂具有运输氧气的能力,人们正在研究其在多种病症中的潜在用途。美国食品药品监督管理局(FDA)近期批准其用于减少血管成形术期间的心肌缺血,这是此类产品在全球获得的首个上市许可。这类产品的众多潜在用途可能使其在未来得到广泛应用,尤其是随着更新、更好的产品不断研发出来。PFC乳剂的消除、分布和组织潴留情况,以及给药后发生的生理变化,一直是众多研究的主题。结果表明,这些制剂可能通过多种机制影响其他药物的药代动力学特性。多项研究表明,输注PFC乳剂后,药物消除和分布会发生显著但不一定一致的变化。这些变化似乎取决于所检测的药物、所使用的乳剂、血液置换程度、所使用的物种以及用于比较的对照。通常,这些变化是时间依赖性的,这表明进行长期研究的重要性。虽然PFC乳剂似乎不会改变药物的肾脏消除,但多项研究表明,这些制剂有可能在接触后数天至数月诱导药物代谢。观察到的药物分布容积变化通常是时间依赖性的,这可能是由于整个循环中正常药物转运的变化和/或膜通透性及细胞转运机制的变化所致。药物转运的变化可能是由于血浆蛋白耗竭或创伤或PFC乳剂作用导致α1-酸性糖蛋白水平升高引起的。PFC乳剂液滴对药物的结合差异很大,且PFC乳剂成分会置换一些与血浆蛋白结合的药物。迄今为止进行的药代动力学研究结果和结论差异很大,这凸显了使用适当对照来确定哪些改变是PFC乳剂特有的重要性。